Form 4 for TEVA TEVA PHARMACEUTICAL INDUSTRIES LTD
Accepted 2022-02-10 00:00:00 ET · period of report 2022-02-08 · accession 0001209191-22-008409 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-02-10 | 2022-02-09 | TEVA | Daniell Richard | EVP, European Commercial | M - OptEx | — | +13.1K | 33.4K | +65% | — |
| D | 2022-02-10 | 2022-02-09 | TEVA | Daniell Richard | EVP, European Commercial | S - Sale+OE | $9.06 | -13.1K | 20.3K | -39% | -$119.0K |
| D | 2022-02-10 | 2022-02-09 | TEVA | Daniell Richard | EVP, European Commercial | M - OptEx | $0.00 | -13.1K | 0 | -100% | $0 |
| D | 2022-02-10 | 2022-02-08 | TEVA | Daniell Richard | EVP, European Commercial | A - Grant | $0.00 | +43.4K | 43.4K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2022-02-09 | M | A | 13,135 | — | 33,415 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. |
| 2 | Common | Ordinary Shares | 2022-02-09 | S | D | 13,135 | $9.06 | 20,280 | D | — | — | (F1) The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.06 to $9.075, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Restricted Share Units | 2022-02-09 | M | D | 13,135 | $0.00 | 0 | D | — · — to — | 13,135 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F5) Restricted share units were granted on February 9, 2018, with 13,135 having vested on each of February 9, 2020, February 9, 2021 and February 9, 2022. |
| 4 | Derivative | Restricted Share Units | 2022-02-08 | A | A | 43,358 | $0.00 | 43,358 | D | — · — to — | 43,358 Ordinary Shares | (F2) Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. (F6) Represents restricted share units received upon satisfaction of performance criteria of performance share units. These units remain subject to time-based vesting and will vest on March 4, 2022. |